Actively Recruiting
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Led by Chongqing Precision Biotech Co., Ltd · Updated on 2025-02-25
80
Participants Needed
1
Research Sites
430 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
CONDITIONS
Official Title
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent
- Diagnosed with relapsed or refractory Multiple Myeloma or other plasma cell disease
- Failed standard chemotherapy regimens or relapsed after complete remission or hematopoietic stem cell transplantation
- Evidence of BCMA expression on cell membranes
- Age between 18 and 75 years
- Expected survival time more than 3 months
- Karnofsky Performance Status (KPS) greater than 60
- No serious mental disorders
- Left ventricular ejection fraction at least 50%
- Sufficient liver function defined by ALT/AST less than or equal to 3 times upper limit of normal and bilirubin less than or equal to 2 times upper limit of normal
- Sufficient kidney function defined by creatinine clearance less than or equal to 2 times upper limit of normal
- Sufficient lung function defined by indoor oxygen saturation at least 92%
- Able to provide single or venous blood samples without contraindications
- Willing and able to follow study visit schedule and protocol requirements
You will not qualify if you...
- History of other malignancies
- Presence of uncontrolled active infections
- Disorders requiring treatment with glucocorticoids
- Active or chronic graft-versus-host disease (GVHD)
- Treatment with T cell inhibitors
- Pregnant or breastfeeding women
- Conditions deemed unsuitable for participation by investigators, including HIV, HCV infection, or intravenous drug addiction
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
920th Hospital of Joint Logistics Support Force
Kunming, Yunnan, China
Actively Recruiting
Research Team
Z
Zhi Yang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here